PCN71 Budget IMPACT Analysis of Zanubrutinib for the Treatment of Adult Patients with Mantle Cell Lymphoma WHO Have Received at Least One PRIOR Therapy from the Payer Perspective in the United States
Dec 1, 2020, 00:00 AM
10.1016/j.jval.2020.08.208
https://www.valueinhealthjournal.com/article/S1098-3015(20)32464-5/fulltext
Section Title :
Section Order :
10160
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32464-5&doi=10.1016/j.jval.2020.08.208